康诺亚生物医药科技成都有限公司
CN
 
CN

Scroll

About Us

Company Profile

Keymed Biosciences Inc. (Stock Code: 02162 HK) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts from world-renowned universities who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. The core leadership team includes the inventors of the first PD-1 antibody drugs that were pioneered and approved in the United States and China. The Company was listed on the main board of Hong Kong Stock Exchange on July 8, 2021.

5_画板 1.png


Management Team

 
 

Milestones

  • April 2022

    ● CMG901 for the treatment of gastric 

    cancer and gastroesophageal junction

     adenocarcinoma was granted the 

    Orphan-drug Designation by the FDA.

    ● FDA granted CMG901 Fast Track

     Designation for unresectable or metastatic

     gastric and gastroesophageal junction 

    cancer which have relapsed and/or are 

    refractory to approved therapies.



  • March 2022

    ● Keymed Biosciences was included as eligible 

    stocks of the Shenzhen-Hong Kong Stock Connect.

    ● Keymed Biosciences released positive result from 

    Phase II clinical trial of CM310 at CRSwNP.



  • January 2022

    ● CM350 was approved for clinical trial by NMPA.

    ● The first patient was dosed in clinical trial of CM355 

       a CD20xCD3 bispecificantibody developed by a joint

       venture between Keymed and InnoCare called Tiannuojiancheng 

       Biopharma, for the treatment of CD20+ B-cell malignancies.


  • November 2021

    ● CM338 was approved for clinical trial by NMPA.

    ● CM326 for AD was approved for clinical trial by NMPA.

    ● Keymed entered into an agreement with CSPC in relation to the 

       exclusive licensing and commercialization of the product CM326 

       in the  treatment of moderate to severe asthma, chronic 

       obstructive pulmonary disease (COPD) and other respiratory

       system diseases.

    ● The Phase IIb clinical study of  CM310 recombinant humanized 

       monoclonal antibody injection (CM310AD002) has completed

       the analysis of unblinded data with preliminary statistics,

       showing positive results. 


  • September 2021

    ● CM336 was approved for clinical trials by NMPA.

    ● CM355 was approved for clinical trials by NMPA.


  • July 2021

    ● Keymed Biosciences Inc. was listed on the Main Board 

       of The Stock Exchange of Hong Kong Limited under the stock 

       code “2162”.


  • March 2021

    ● CM326 was approved for clinical trials by NMPA.

    ● CMG901 was approved for clinical trials by FDA.

    ● Keymed entered into an agreement with CSPC in relation to the exclusive licensing and commercialization of the product CM310 in the treatment of moderate to severe asthma, chronic  obstructive pulmonary disease (COPD) and other respiratory 

    system diseases .


  • October-December 2020

    ● CMG901 was approved for clinical trials in October and administered to the first patient in December.

    ● CM313 was approved for clinical trials in November.

    ● Phase IIb clinical trial was initiated in November to evaluate the effect of CM310 in patients with moderate to severe atopicdermatitis, and phase II trial was initiated in December to evaluatethe effect of CM310 in patients with chronic sinusitis with polyps.


  • May-June 2020

    ● In May 2020, CM312 was approved for clinical trials by NMPA.

    ● Phase Ib/IIa clinical trial was initiated in June to evaluate the effect of CM310 in patients with moderate to severe atopic dermatitis.


  • July-September 2019

    ● CM310 was approved for clinical trials in July, and the phase I trial was initiated in September.

  • September 2016

    ● Established in Chengdu as an innovative medicine R&D company.


  • 2022年April 2022

    ● CMG901 for the treatment of gastric 

    cancer and gastroesophageal junction

     adenocarcinoma was granted the 

    Orphan-drug Designation by the FDA.

    ● FDA granted CMG901 Fast Track

     Designation for unresectable or metastatic

     gastric and gastroesophageal junction 

    cancer which have relapsed and/or are 

    refractory to approved therapies.



  • 2022年March 2022

    ● Keymed Biosciences was included as eligible 

    stocks of the Shenzhen-Hong Kong Stock Connect.

    ● Keymed Biosciences released positive result from 

    Phase II clinical trial of CM310 at CRSwNP.



  • 2022年January 2022

    ● CM350 was approved for clinical trial by NMPA.

    ● The first patient was dosed in clinical trial of CM355 

       a CD20xCD3 bispecificantibody developed by a joint

       venture between Keymed and InnoCare called Tiannuojiancheng 

       Biopharma, for the treatment of CD20+ B-cell malignancies.


  • 2021年November 2021

    ● CM338 was approved for clinical trial by NMPA.

    ● CM326 for AD was approved for clinical trial by NMPA.

    ● Keymed entered into an agreement with CSPC in relation to the 

       exclusive licensing and commercialization of the product CM326 

       in the  treatment of moderate to severe asthma, chronic 

       obstructive pulmonary disease (COPD) and other respiratory

       system diseases.

    ● The Phase IIb clinical study of  CM310 recombinant humanized 

       monoclonal antibody injection (CM310AD002) has completed

       the analysis of unblinded data with preliminary statistics,

       showing positive results. 


  • 2021年September 2021

    ● CM336 was approved for clinical trials by NMPA.

    ● CM355 was approved for clinical trials by NMPA.


  • 2021年July 2021

    ● Keymed Biosciences Inc. was listed on the Main Board 

       of The Stock Exchange of Hong Kong Limited under the stock 

       code “2162”.


  • 2021年March 2021

    ● CM326 was approved for clinical trials by NMPA.

    ● CMG901 was approved for clinical trials by FDA.

    ● Keymed entered into an agreement with CSPC in relation to the exclusive licensing and commercialization of the product CM310 in the treatment of moderate to severe asthma, chronic  obstructive pulmonary disease (COPD) and other respiratory 

    system diseases .


  • 2020年October-December 2020

    ● CMG901 was approved for clinical trials in October and administered to the first patient in December.

    ● CM313 was approved for clinical trials in November.

    ● Phase IIb clinical trial was initiated in November to evaluate the effect of CM310 in patients with moderate to severe atopicdermatitis, and phase II trial was initiated in December to evaluatethe effect of CM310 in patients with chronic sinusitis with polyps.


  • 2020年May-June 2020

    ● In May 2020, CM312 was approved for clinical trials by NMPA.

    ● Phase Ib/IIa clinical trial was initiated in June to evaluate the effect of CM310 in patients with moderate to severe atopic dermatitis.


  • 2019年July-September 2019

    ● CM310 was approved for clinical trials in July, and the phase I trial was initiated in September.

  • 2016年September 2016

    ● Established in Chengdu as an innovative medicine R&D company.


2022

2021

2020

2019

2016

Corporate Culture

  • Vision
     
    Vision
    Vision

    We are committed to establishing a high-tech company that represents the world's most advanced level of innovative therapeutic antibody R&D and addressing the urgent unmet clinical needs.

  • Mission
     
    mission
    Mission
    Mission

    We dedicate to bring cost-effective medicines to patients globally, with the mission of "continuous pursuit of innovation and excellence".


  • Value
     
    Value
    Value
    Value

    Following patient - oriented principle, we are committed to pursuing higher standards of social value output, and bringing more hope to patients around the world.